Single User License
INR 136040
Site License
INR 272080
Corporate User License
INR 408120

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


T-Cell Leukemia-Pipeline Review, H1 2015

T-Cell Leukemia-Pipeline Review, H1 2015


  Request for Sample Report

Executive Summary

T-Cell Leukemia-Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'T-Cell Leukemia-Pipeline Review, H1 2015', provides an overview of the T-Cell Leukemia's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for T-Cell Leukemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for T-Cell Leukemia and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of T-Cell Leukemia

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for T-Cell Leukemia and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the T-Cell Leukemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the T-Cell Leukemia pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for T-Cell Leukemia

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding T-Cell Leukemia pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 6

Introduction 7

Global Markets Direct Report Coverage 7

T-Cell Leukemia Overview 8

Therapeutics Development 9

Pipeline Products for T-Cell Leukemia-Overview 9

Pipeline Products for T-Cell Leukemia-Comparative Analysis 10

T-Cell Leukemia-Therapeutics under Development by Companies 11

T-Cell Leukemia-Therapeutics under Investigation by Universities/Institutes 12

T-Cell Leukemia-Pipeline Products Glance 13

Clinical Stage Products 13

Early Stage Products 14

T-Cell Leukemia-Products under Development by Companies 15

T-Cell Leukemia-Products under Investigation by Universities/Institutes 16

T-Cell Leukemia-Companies Involved in Therapeutics Development 17

Applied Immune Technologies Ltd 17

Astellas Pharma Inc. 18

Bristol-Myers Squibb Company 19

Celgene Corporation 20

iDD biotech SAS 21

Kyowa Hakko Kirin Co., Ltd. 22

MediGene AG 23

Nippon Kayaku Co., Ltd. 24

Pfizer Inc. 25

Pharmacyclics, Inc. 26

Sanofi 27

Stemline Therapeutics, Inc. 28

Theravectys S.A. 29

Tolero Pharmaceuticals, Inc. 30

T-Cell Leukemia-Therapeutics Assessment 31

Assessment by Monotherapy Products 31

Assessment by Target 32

Assessment by Mechanism of Action 34

Assessment by Route of Administration 36

Assessment by Molecule Type 38

Drug Profiles 40

AGS-67E-Drug Profile 40

Product Description 40

Mechanism of Action 40

R&D Progress 40

alemtuzumab-Drug Profile 41

Product Description 41

Mechanism of Action 41

R&D Progress 41

Antibody to Inhibit HLA-A2 for Neurology, Infectious Diseases and T-Cell Leukemia-Drug Profile 44

Product Description 44

Mechanism of Action 44

R&D Progress 44

BMS-906024-Drug Profile 45

Product Description 45

Mechanism of Action 45

R&D Progress 45

Cell Therapy to Target CD38 for cancer-Drug Profile 47

Product Description 47

Mechanism of Action 47

R&D Progress 47

IDD-003-Drug Profile 48

Product Description 48

Mechanism of Action 48

R&D Progress 48

INA-01-Drug Profile 49

Product Description 49

Mechanism of Action 49

R&D Progress 49

lenalidomide-Drug Profile 50

Product Description 50

Mechanism of Action 50

R&D Progress 50

MMIG-202-Drug Profile 54

Product Description 54

Mechanism of Action 54

R&D Progress 54

mogamulizumab-Drug Profile 55

Product Description 55

Mechanism of Action 55

R&D Progress 55

Monoclonal Antibodies to Antagonize TCR for Leukemia and Autoimmune Disease-Drug Profile 57

Product Description 57

Mechanism of Action 57

R&D Progress 57

Monoclonal Antibody to Target CCR9 for T Lymphoblastic Leukemia-Drug Profile 58

Product Description 58

Mechanism of Action 58

R&D Progress 58

NK-314-Drug Profile 59

Product Description 59

Mechanism of Action 59

R&D Progress 59

Oncolytic Virus to Target Glycoprotein gp160 for T-cell Leukemia-Drug Profile 60

Product Description 60

Mechanism of Action 60

R&D Progress 60

PCI-34051-Drug Profile 61

Product Description 61

Mechanism of Action 61

R&D Progress 61

PF-03084014-Drug Profile 62

Product Description 62

Mechanism of Action 62

R&D Progress 62

SL-101-Drug Profile 64

Product Description 64

Mechanism of Action 64

R&D Progress 64

Synthetic Peptide for Oncology and Male health-Drug Profile 65

Product Description 65

Mechanism of Action 65

R&D Progress 65

THV-02-Drug Profile 66

Product Description 66

Mechanism of Action 66

R&D Progress 66

TP-0903-Drug Profile 67

Product Description 67

Mechanism of Action 67

R&D Progress 67

T-Cell Leukemia-Recent Pipeline Updates 68

T-Cell Leukemia-Dormant Projects 85

T-Cell Leukemia-Discontinued Products 86

T-Cell Leukemia-Product Development Milestones 87

Featured News & Press Releases 87

Feb 04, 2015: THERAVECTYS Obtains Orphan Drug Designation from the European Medicines Agency for Its Lentiviral Vector-Based Therapeutic Vaccine against Adult T-Cell Leukemia and Lymphoma 87

Dec 18, 2014: Approval for Additional Indication for Chemotherapy-Native CCR4-positive ATL of Mogamulizumab 88

Sep 29, 2014: Pfizer And Kyowa Hakko Kirin To Collaborate On Immuno-Oncology Combination Study 88

Aug 23, 2012: Kyowa Hakko Kirin Initiates Pivotal Phase II Trial Of Mogamulizumab In Patients With Adult T-cell Leukemia-Lymphoma In US And Europe 89

Jul 19, 2012: Application Seeking Approval for Additional Indication for ATL, PTCL and CTCL of Mogamulizumab 89

May 29, 2012: Kyowa Hakko Kirin Launches POTELIGEO Injection In Japan 90

Jan 25, 2012: Study Shows Leukemia Drug Kills Cancerous T-cells While Sparing Normal Immunity 90

Dec 07, 2010: Kyowa Hakko Kirin Announces Results From Japan Phase II Clinical Trial Of KW-0761 In Adult T-Cell Leukemia-Lymphoma 91

Appendix 92

Methodology 92

Coverage 92

Secondary Research 92

Primary Research 92

Expert Panel Validation 92

Contact Us 92

Disclaimer 93

List of Tables

Number of Products under Development for T-Cell Leukemia, H1 2015 9

Number of Products under Development for T-Cell Leukemia-Comparative Analysis, H1 2015 10

Number of Products under Development by Companies, H1 2015 11

Number of Products under Investigation by Universities/Institutes, H1 2015 12

Comparative Analysis by Clinical Stage Development, H1 2015 13

Comparative Analysis by Early Stage Development, H1 2015 14

Products under Development by Companies, H1 2015 15

Products under Investigation by Universities/Institutes, H1 2015 16

T-Cell Leukemia-Pipeline by Applied Immune Technologies Ltd, H1 2015 17

T-Cell Leukemia-Pipeline by Astellas Pharma Inc., H1 2015 18

T-Cell Leukemia-Pipeline by Bristol-Myers Squibb Company, H1 2015 19

T-Cell Leukemia-Pipeline by Celgene Corporation, H1 2015 20

T-Cell Leukemia-Pipeline by iDD biotech SAS, H1 2015 21

T-Cell Leukemia-Pipeline by Kyowa Hakko Kirin Co., Ltd., H1 2015 22

T-Cell Leukemia-Pipeline by MediGene AG, H1 2015 23

T-Cell Leukemia-Pipeline by Nippon Kayaku Co., Ltd., H1 2015 24

T-Cell Leukemia-Pipeline by Pfizer Inc., H1 2015 25

T-Cell Leukemia-Pipeline by Pharmacyclics, Inc., H1 2015 26

T-Cell Leukemia-Pipeline by Sanofi, H1 2015 27

T-Cell Leukemia-Pipeline by Stemline Therapeutics, Inc., H1 2015 28

T-Cell Leukemia-Pipeline by Theravectys S.A., H1 2015 29

T-Cell Leukemia-Pipeline by Tolero Pharmaceuticals, Inc., H1 2015 30

Assessment by Monotherapy Products, H1 2015 31

Number of Products by Stage and Target, H1 2015 33

Number of Products by Stage and Mechanism of Action, H1 2015 35

Number of Products by Stage and Route of Administration, H1 2015 37

Number of Products by Stage and Molecule Type, H1 2015 39

T-Cell Leukemia Therapeutics-Recent Pipeline Updates, H1 2015 68

T-Cell Leukemia-Dormant Projects, H1 2015 85

T-Cell Leukemia-Discontinued Products, H1 2015 86

List of Figures

Number of Products under Development for T-Cell Leukemia, H1 2015 9

Number of Products under Development for T-Cell Leukemia-Comparative Analysis, H1 2015 10

Number of Products under Development by Companies, H1 2015 11

Number of Products under Investigation by Universities/Institutes, H1 2015 12

Comparative Analysis by Clinical Stage Development, H1 2015 13

Comparative Analysis by Early Stage Products, H1 2015 14

Assessment by Monotherapy Products, H1 2015 31

Number of Products by Top 10 Targets, H1 2015 32

Number of Products by Stage and Top 10 Targets, H1 2015 32

Number of Products by Top 10 Mechanism of Actions, H1 2015 34

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 34

Number of Products by Top 10 Routes of Administration, H1 2015 36

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 37

Number of Products by Top 10 Molecule Types, H1 2015 38

Number of Products by Stage and Top 10 Molecule Types, H1 2015 39

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Applied Immune Technologies Ltd

Astellas Pharma Inc.

Bristol-Myers Squibb Company

Celgene Corporation

iDD biotech SAS

Kyowa Hakko Kirin Co., Ltd.

MediGene AG

Nippon Kayaku Co., Ltd.

Pfizer Inc.

Pharmacyclics, Inc.

Sanofi

Stemline Therapeutics, Inc.

Theravectys S.A.

Tolero Pharmaceuticals, Inc.

T-Cell Leukemia Therapeutic Products under Development, Key Players in T-Cell Leukemia Therapeutics, T-Cell Leukemia Pipeline Overview, T-Cell Leukemia Pipeline, T-Cell Leukemia Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com